Mapracorat

DB12041InvestigationalSmall molecule

Mapracorat has been investigated for the treatment of Eczema and Atopic Dermatitis.

Mechanism: Pharmacologically active on Glucocorticoid receptor
Curator reviewed
Formula / weight: C₂₅H₂₆F₄N₂O₂ · 462.489 g/mol (avg)
Code names: BOL-303242-X · ZK-245186

Resolves to

Compound

Structure

InChIKeyVJGFOYBQOIPQFY-XMMPIXPASA-NSMILESCC1=CC=C2C(NC[C@](O)(CC(C)(C)C3=CC(F)=CC4=C3OCC4)C(F)(F)F)=CC=CC2=N1

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mapracorat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.